Estimation of eligibility for proprotein convertase subtilisin/kexin type 9 inhibitors and associated costs based on the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk): Insights from the Department of Veterans Affairs
Document Type
Article
Department
Office of the Provost; Cardiology
Publication (Name of Journal)
Circulation
DOI
10.1161/CIRCULATIONAHA.117.028503
Recommended Citation
Virani, S. S.,
Akeroyd, J. M.,
Nambi, V.,
Heidenreich, P. A.,
Morris, P. B.,
Nasir, K.,
Michos, E. D.,
Bittner, V. A.,
Petersen, L. A.,
Ballantyne, C. M.
(2017). Estimation of eligibility for proprotein convertase subtilisin/kexin type 9 inhibitors and associated costs based on the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk): Insights from the Department of Veterans Affairs. Circulation, 135(25), 2572-2574.
Available at:
https://ecommons.aku.edu/provost_office/683
COinS
Comments
Abstract is not provided by the author/publisher. This work was published before the author joined Aga Khan University.